ParkinsonCanadaV1, Main, Exploration, bibRecord, 002441

Rasagiline: a review of its use in the management of Parkinson's disease.

Identifieur interne : 002441 ( Main/Exploration ); précédent : 002440; suivant : 002442

Rasagiline: a review of its use in the management of Parkinson's disease.

Auteurs : Vicki Oldfield [États-Unis] ; Gillian M. Keating ; Caroline M. Perry

Source :

Drugs [ 0012-6667 ] ; 2007.

RBID : pubmed:17683172

English descriptors

KwdEn :
- Animals, Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Drug Therapy, Combination, Humans, Indans (adverse effects), Indans (pharmacokinetics), Indans (pharmacology), Indans (therapeutic use), Levodopa (therapeutic use), Monoamine Oxidase Inhibitors (adverse effects), Monoamine Oxidase Inhibitors (pharmacokinetics), Monoamine Oxidase Inhibitors (pharmacology), Monoamine Oxidase Inhibitors (therapeutic use), Parkinson Disease (drug therapy).
MESH :
- chemical , adverse effects : Antiparkinson Agents, Indans, Monoamine Oxidase Inhibitors.
- chemical , pharmacokinetics : Antiparkinson Agents, Indans, Monoamine Oxidase Inhibitors.
- chemical , pharmacology : Antiparkinson Agents, Indans, Monoamine Oxidase Inhibitors.
- chemical , therapeutic use : Antiparkinson Agents, Indans, Levodopa, Monoamine Oxidase Inhibitors.
- drug therapy : Parkinson Disease.
- Animals, Drug Therapy, Combination, Humans.

Abstract

Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of Parkinson's disease. Results of well designed clinical studies indicate that rasagiline is effective as initial monotherapy and improves Parkinson's symptomatology in patients with early Parkinson's disease. In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. Rasagiline is generally well tolerated as monotherapy and adjunctive therapy and is administered once daily. Thus, rasagiline, administered as a simple and convenient dosage regimen, is a well tolerated and effective option for monotherapy in patients with early Parkinson's disease and for adjunctive therapy in patients with moderate to advanced disease.

PubMed: 17683172

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rasagiline: a review of its use in the management of Parkinson's disease.</title>
<author><name sortKey="Oldfield, Vicki" sort="Oldfield, Vicki" uniqKey="Oldfield V" first="Vicki" last="Oldfield">Vicki Oldfield</name>
<affiliation wicri:level="2"><nlm:affiliation>Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keating, Gillian M" sort="Keating, Gillian M" uniqKey="Keating G" first="Gillian M" last="Keating">Gillian M. Keating</name>
</author>
<author><name sortKey="Perry, Caroline M" sort="Perry, Caroline M" uniqKey="Perry C" first="Caroline M" last="Perry">Caroline M. Perry</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17683172</idno>
<idno type="pmid">17683172</idno>
<idno type="wicri:Area/PubMed/Corpus">001109</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001109</idno>
<idno type="wicri:Area/PubMed/Curation">001109</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001109</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001109</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001109</idno>
<idno type="wicri:Area/Ncbi/Merge">000800</idno>
<idno type="wicri:Area/Ncbi/Curation">000800</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000800</idno>
<idno type="wicri:doubleKey">0012-6667:2007:Oldfield V:rasagiline:a:review</idno>
<idno type="wicri:Area/Main/Merge">002667</idno>
<idno type="wicri:Area/Main/Curation">002441</idno>
<idno type="wicri:Area/Main/Exploration">002441</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rasagiline: a review of its use in the management of Parkinson's disease.</title>
<author><name sortKey="Oldfield, Vicki" sort="Oldfield, Vicki" uniqKey="Oldfield V" first="Vicki" last="Oldfield">Vicki Oldfield</name>
<affiliation wicri:level="2"><nlm:affiliation>Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keating, Gillian M" sort="Keating, Gillian M" uniqKey="Keating G" first="Gillian M" last="Keating">Gillian M. Keating</name>
</author>
<author><name sortKey="Perry, Caroline M" sort="Perry, Caroline M" uniqKey="Perry C" first="Caroline M" last="Perry">Caroline M. Perry</name>
</author>
</analytic>
<series><title level="j">Drugs</title>
<idno type="ISSN">0012-6667</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Indans (adverse effects)</term>
<term>Indans (pharmacokinetics)</term>
<term>Indans (pharmacology)</term>
<term>Indans (therapeutic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Monoamine Oxidase Inhibitors (adverse effects)</term>
<term>Monoamine Oxidase Inhibitors (pharmacokinetics)</term>
<term>Monoamine Oxidase Inhibitors (pharmacology)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indans</term>
<term>Levodopa</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of Parkinson's disease. Results of well designed clinical studies indicate that rasagiline is effective as initial monotherapy and improves Parkinson's symptomatology in patients with early Parkinson's disease. In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. Rasagiline is generally well tolerated as monotherapy and adjunctive therapy and is administered once daily. Thus, rasagiline, administered as a simple and convenient dosage regimen, is a well tolerated and effective option for monotherapy in patients with early Parkinson's disease and for adjunctive therapy in patients with moderate to advanced disease.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><noCountry><name sortKey="Keating, Gillian M" sort="Keating, Gillian M" uniqKey="Keating G" first="Gillian M" last="Keating">Gillian M. Keating</name>
<name sortKey="Perry, Caroline M" sort="Perry, Caroline M" uniqKey="Perry C" first="Caroline M" last="Perry">Caroline M. Perry</name>
</noCountry>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Oldfield, Vicki" sort="Oldfield, Vicki" uniqKey="Oldfield V" first="Vicki" last="Oldfield">Vicki Oldfield</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002441 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002441 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:17683172
   |texte=   Rasagiline: a review of its use in the management of Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:17683172" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Rasagiline: a review of its use in the management of Parkinson's disease.

Rasagiline: a review of its use in the management of Parkinson's disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.